MRNA · BIOTECH · EARNINGS

Stéphane Bancel's Moderna jumped after a surprise profit and a raised outlook for its first year of growth since 2022

Third-quarter revenue rose 29% to $1.31 billion against a $885 million estimate, and Moderna now expects 2026 sales to grow 15% to 25%. It also nearly doubled its year-end cash forecast.

Invested Alpha Staff · 5 min read

Illustration: Invested Alpha

For most of the past three years, Moderna's story has been about shrinking: lower Covid vaccine sales, deep cost cuts and repeated losses. On Friday the company reported something it has not shown in a while, a quarter with rising sales and a profit, and said 2026 will be its first year of revenue growth since 2022.

The numbers

Third-quarter revenue rose 29% to $1.31 billion, well above the $885.1 million analysts polled by LSEG expected, CNBC reported. Moderna earned $162 million, or 38 cents a share, compared with a net loss of $200 million, or 51 cents a share, a year earlier. Analysts had expected a loss of $1.25 a share.

Revenue was $780 million in the U.S. and $533 million in international markets, boosted by higher Covid vaccine sales abroad and deliveries under long-term government partnerships, according to CNBC. The Motley Fool's transcript of the earnings call showed year-to-date international revenue of $900 million, already $200 million more than in all of 2025.

Costs fell at the same time. Research and development spending dropped 27% to $583 million as several late-stage studies wound down, Sharecast reported, and Moderna said its cash costs declined 10% to $1.0 billion in the quarter.

The raised outlook

Moderna now expects 2026 revenue to grow 15% to 25%, up from its previous guidance of up to 10%. It lowered its full-year research and development forecast to about $2.7 billion from $2.9 billion and raised its forecast for year-end cash and investments to $8.1 billion to $8.3 billion, from $4.7 billion to $5.2 billion, helped by proceeds from a convertible note sale, the company said.

"The new product and the diversification of geography is what has led to such a strong Q3." - Stéphane Bancel, Moderna CEO, in an interview with CNBC

Bancel told CNBC that the company is seeing the full-year impact of its next-generation Covid vaccine, which won U.S. approval in May 2025, and that its new stand-alone flu shot, approved in the U.S. in August, will have a limited launch this year given the timing. In a separate interview on CNBC's "Squawk Box," he said expansion in Canada, the U.K. and Asia also helped.

"It's the sales that are stronger and the costs that are also lower." - Stéphane Bancel, on CNBC's "Squawk Box"

Get Free Investment Ideas In Your Inbox Every Morning

We follow the latest trends so you don't have to.

Get the free newsletter

How the stock traded

Moderna shares closed up 5.27% at $254.19, according to Yahoo Finance data. The stock traded as high as $263.44 earlier in the session, a gain of 9.1%, Benzinga reported, and CNBC put the midday gain at 7%. The pullback from the highs came as the broader market turned mixed, with the Dow ending lower.

The balance sheet

The company's cash and investments stood at $8 billion at the end of the quarter, up from $6.9 billion in the second quarter, according to the call transcript. That came after Moderna issued $3 billion of zero-percent convertible notes, which brought in net proceeds of $2.6 billion, and despite a $950 million litigation settlement payment.

In its quarterly letter, Moderna said it has cut its cash costs and investments over the past three years from $9 billion to under $4 billion while continuing to advance its pipeline.

The pipeline

Beyond respiratory vaccines, investors are watching Moderna's cancer program with Merck. On the call, the company cited Phase 3 melanoma data showing a 42% reduction in the risk of recurrence or death for patients receiving its experimental therapy intismeran together with Merck's Keytruda, according to The Motley Fool's transcript.

What carries into next week

The quarter shows Moderna can grow again and make money doing it, but its business remains seasonal, with Covid vaccine contracts typically set early in the year, as Bancel noted. The next questions are how its new flu vaccine launches in the U.S. and whether international demand holds up into 2027.

This article is for informational purposes only and is not investment advice.

Get Free Investment Ideas In Your Inbox Every Morning

We follow the latest trends so you don't have to.

Unsubscribe anytime.